Cerevel Therapeutics (CERE)
(Delayed Data from NSDQ)
$42.47 USD
+0.40 (0.95%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $42.44 -0.03 (-0.07%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CERE 42.47 +0.40(0.95%)
Will CERE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CERE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CERE
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
CERE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
Cerevel Therapeutics Holdings, Inc. (CERE)'s Technical Outlook is Bright After Key Golden Cross
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
Other News for CERE
Polaris Global Equity Composite Q1 2024 Commentary
Hold Rating Maintained for Cerevel Post-Positive Phase 3 Data Amid Pending AbbVie Acquisition
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug